| B43 | 48 weeks efficacy and tolerability of dolutegravir (DTG) + lamivudine (3TC) in adult HIV naïve patients. A multicenter real life cohort | E-poster | New strategies (2DR, rapid start) |
| B43 | Immediate ART is feasible during the COVID-19 pandemic | E-poster | New strategies (2DR, rapid start) |
| B45 | New generation of HYBRID CAR-T cells efficiently kill HIV infected cells and neutralize cell-free virus | On-demand oral abstract session | Immune-based therapy trials |
| B46 | Lower HIV reservoir size in individuals who maintain higher CD4+ T cells counts prior to antiretroviral therapy initiation: the Strategic Timing of Antiretroviral Treatment (START) HIV reservoir study | E-poster | Cure interventions |
| B49 | Food rescue programs in food-insecure PWLH in Baylor Mwanza-Tanzania: a descriptive study | E-poster | Nutrition |
| B52 | Update on neural tube defects with antiretoviral exposure in the Tsepamo study, Botswana | E-poster | Sex-specific issues of ART efficacy, adverse reactions and complications |
| B53 | Prevalence of depression among postpartum women on Isoniazid-Preventive Therapy and Efavirenz-based treatment for HIV'an exploratory objective of the IMPAACT P1078 randomized trial | E-poster | Pregnancy (clinical management issues and pharmacokinetics) |
| B53 | Adverse perinatal outcomes associated with timing of initiation of antiretroviral therapy: systematic review and meta-analysis | E-poster | Pregnancy (clinical management issues and pharmacokinetics) |
| B53 | Comparable pregnancy outcomes for HIV-uninfected and HIV-infected women on antiretroviral treatment in Kenya | E-poster | Pregnancy (clinical management issues and pharmacokinetics) |
| B53 | A comparative multi-country analysis of the impact of COVID-19 on HIV services for pregnant and breastfeeding women and their infants | E-poster | Pregnancy (clinical management issues and pharmacokinetics) |